Thirty-eight new grants support research in ALS, central core disease, spinal muscular atrophy, muscular dystrophy, and other diseases in MDA's program
posted on August 17, 2010 - 6:39pm
MDA has awarded 38 new research grants totaling more than $14 million and covering more than a dozen neuromuscular diseases.
MDA's Board of Directors met in Los Angeles July 16, where it reviewed and approved the new grants based on recommendations from the MDA Scientific and Medical Advisory Committees. Grants were scored and recommended for approval based on the capabilities of the...
In this first of several reports on MDA's Clinical Conference, the role of genetics and immunology in different neuromuscular diseases is described
posted on March 19, 2012 - 3:08pm
More than 500 physicians, allied health care professionals and MDA staff attended the MDA's 2012 Clinical Conference in Las Vegas, March 4-7.
The program emphasized:
MDA will sponsor four symposia addressing specific roadblocks and moving forward with therapy development for neuromuscular disease
posted on May 17, 2012 - 6:15pm
This month, MDA is launching a new U.S.-based symposium series to address important topics and ultimately to accelerate therapy development for neuromuscular diseases.
"MDA’s new symposium series is designed to address cutting-edge issues in neuromuscular disease research," said Sanjay Bidichandani, MDA's vice president of research. "Science is advancing at a rapid pace, and these small and...
Innovative research aims to deepen understanding of the molecular cause of FSHD, with the goal of developing therapies
posted on April 5, 2010 - 5:23pm
MDA has awarded two grants for research aimed at determining the precise molecular causes of facioscapulohumeral dystrophy (FSHD), and developing therapies for the disease.
MDA and Friends of FSH Research (FFSHR) based in Kirkland, Wash., will jointly fund a two-year, $200,000 grant to Joel Chamberlain, an assistant professor of medical genetics at the University of Washington in Seattle.
The shorter-than-normal dystrophin protein produced via an experimental exon-skipping drug allows proper localization of proteins at the muscle-fiber membrane
posted on February 8, 2012 - 2:45pm
Shortened versions of the muscle protein dystrophin — produced by skipping a section of genetic instructions called exon 51 — appear to be functional, says a new report from the United Kingdom.
MDA Venture Philanthropy—not your father's research program
posted on April 1, 2009 - 3:45pm
An increasingly popular trend in funding research projects is “venture philanthropy,” which applies effective business principles and practices to nonprofit goals.
Now, MDA has put this model to work for its research program by creating a new nonprofit spin-off, MDA Venture Philanthropy (MVP), that seeks to overcome barriers and speed the development of drugs for the diseases in MDA’s program.
An MDA-sponsored meeting explored progress in five key therapeutic strategies under development for neuromuscular diseases
posted on March 18, 2011 - 3:30pm
Moving therapeutic strategies from the laboratory to clinical trials and ultimately to the market as treatments was the theme of the MDA National Scientific Conference held March 13-16, 2011, in Las Vegas.
Some 300 people attended the conference, the first in a planned series of such MDA-sponsored meetings that will emphasize new research and current medical care. The majority of presenters and...
New strategies are positioning MDA's research program for success
posted on January 1, 2008 - 3:06pm
The fast pace of scientific progress in this first decade of the 21st century, coupled with expanding knowledge about human genetics and disease, has led to significant changes in the way MDA approaches research.
posted on January 1, 2009 - 6:54pm
Updated MD-CARE Act is now law
The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2008 received final Congressional approval on Sept. 27 and were signed into law by President Bush Oct. 8.
The latest advances in diagnosis, medical management and the status of therapy development for neuromuscular diseases were covered at MDA's 2012 Clinical Conference
posted on March 9, 2012 - 2:28pm
The 2012 MDA Clinical Conference, held in Las Vegas March 4 -7, gave more than 500 attendees an opportunity to learn from top experts about the latest advances in diagnosis, medical management and emerging therapies for neuromuscular diseases.
